AGP Executive Report
Last update: 7 hours agoReal-World RA Care: A new Italian chart-based study (9 tertiary centres, 2020–2022) found JAK inhibitors for rheumatoid arthritis cut disease activity over 12 months, with DAS28-CRP dropping from 3.9 to 2.4 and SDAI from 19.8 to 8.1, with no major effectiveness or safety differences by diabetes status, cardiometabolic multimorbidity, or age. Cancer Drug Update: J&J’s Rybrevant (amivantamab) plus chemotherapy in EGFR exon 20 insertion NSCLC was linked to the longest median overall survival reported in a Phase III trial (34.3 vs 27.9 months with chemo), including durability despite crossover. Public Health & Access: After a Kaiser-Renown insurance change, 4,500 people were told to find new doctors—another reminder of how coverage shifts can disrupt care continuity. Food Security & Nutrition: FAO chief QU Dongyu visited Italy’s rice hub in Vercelli, stressing rice’s role in global food security and calling for long-term strategies to boost productivity while protecting natural resources. Workplace Safety: Back-to-school traffic analysis flagged school-area congestion risks, with school drop-offs driving 20–30% of morning traffic.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
